throbber
Case 1:15-cv-01684-JBS-JS Document 1 Filed 03/06/15 Page 1 of 13 PageID: 1
`
`LAW OFFICES
`DECHERT LLP
`A PENNSYLVANIA LIMITED LIABILITY PARTNERSHIP
`902 CARNEGIE CENTER, SUITE 500
`PRINCETON, NEW JERSEY 08540-6531
`(609) 955-3200
`ATTORNEYS FOR PLAINTIFFS BAXTER HEALTHCARE CORPORATION,
`BAXTER INTERNATIONAL INC., AND BAXTER HEALTHCARE S.A.
`
`
`
`UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF NEW JERSEY
`
`BAXTER HEALTHCARE
`CORPORATION, BAXTER
`INTERNATIONAL INC., and
`BAXTER HEALTHCARE S.A.,
`
`Plaintiffs,
`
`v.
`
`C.A. No.
`
`
`
`
`
`
`
`
`
`
`SAGENT PHARMACEUTICALS
`INC.,
`
`
`
`Defendant.
`
`COMPLAINT
`
`Plaintiffs Baxter Healthcare Corporation (“Baxter Healthcare”), Baxter International Inc.
`
`
`
`
`
`(“Baxter International”), and Baxter Healthcare S.A. (“Baxter HAS”) (collectively, “Baxter” or
`
`“Plaintiffs”), for their Complaint against defendant Sagent Pharmaceuticals Inc. (“Sagent” or
`
`“Defendant”) allege as follows:
`
`PARTIES
`
`1.
`
`Plaintiff Baxter International is a corporation incorporated in Delaware, having its
`
`principal place of business at One Baxter Parkway, Deerfield, IL 60015.
`
`- 1 -
`
`

`
`Case 1:15-cv-01684-JBS-JS Document 1 Filed 03/06/15 Page 2 of 13 PageID: 2
`
`2.
`
`Plaintiff Baxter Healthcare is a corporation incorporated in Delaware, having its
`
`principal place of business at One Baxter Parkway, Deerfield, IL 60015. Baxter Healthcare is a
`
`wholly owned subsidiary of Baxter International.
`
`3.
`
`Plaintiff Baxter HSA is a corporation incorporated in Switzerland, having its
`
`principal place of business at Hertistrasse 2, Wallisellen, CH-8304, Switzerland. Baxter HSA is
`
`a wholly owned subsidiary of Baxter International.
`
`4.
`
`Baxter is a global healthcare company that develops, manufactures and markets
`
`products for people with hemophilia, immune disorders, infectious diseases, kidney disease,
`
`trauma, and other chronic and acute medical conditions.
`
`5.
`
`Upon information and belief, Sagent is a corporation incorporated in Delaware,
`
`having its principal place of business at 1901 N. Roselle Road, Suite 700, Schaumburg, Illinois
`
`60195.
`
`6.
`
`Upon information and belief, Sagent is a specialty pharmaceutical company
`
`focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical
`
`products for sale primarily in the United States of America.
`
`NATURE OF ACTION
`
`7.
`
`This is an action for infringement of United States Patent Nos. 6,310,094 (“the
`
`‘094 Patent”) and 6,528,540 (“the ‘540 Patent”) (collectively, “the Patents-in-Suit”). This action
`
`is based upon the Patent Laws of the United States, 35 U.S.C. § 100, et seq.
`
`- 2 -
`
`

`
`Case 1:15-cv-01684-JBS-JS Document 1 Filed 03/06/15 Page 3 of 13 PageID: 3
`
`JURISDICTION AND VENUE
`
`8.
`
`This Court has jurisdiction over the subject matter of this action pursuant to 28
`
`U.S.C. §§ 1331 and 1338(a) (patent infringement). Venue is proper in this district pursuant to 28
`
`U.S.C. §§ 1391(b), 1391(c) and 1400(b).
`
`9.
`
`This Court has personal jurisdiction over Sagent because, inter alia, they have
`
`committed – or aided, abetted, planned, contributed to, or participated in the commission of –
`
`tortious conduct which will lead to foreseeable harm and injury to Baxter in the State of New
`
`Jersey, and in doing so, Sagent has purposefully directed its activities at the residents of this
`
`forum.
`
`10.
`
`This Court also has personal jurisdiction over Sagent because, inter alia, they
`
`have maintained continuous and systematic contacts with the State of New Jersey and this
`
`District.
`
`11.
`
`Upon information and belief, Sagent develops, manufactures, sources, and
`
`markets injectable pharmaceutical products that it sells throughout the United States, including in
`
`the State of New Jersey, including by making and shipping into this judicial district, or by
`
`offering to sell or selling, or causing others to offer to sell or sell, generic pharmaceutical
`
`products in this judicial district. Upon information and belief, Sagent derives substantial revenue
`
`from goods used or consumed or services rendered in this judicial district.
`
`12.
`
`Sagent’s 10-K claims, for instance, that Sagent is a specialty pharmaceutical
`
`company focused on developing, manufacturing, sourcing and marketing injectable
`
`pharmaceutical products, which Sagent sells primarily in the United States of America. Upon
`
`information and belief, Sagent derives revenue from its sales in New Jersey and is registered
`
`- 3 -
`
`

`
`Case 1:15-cv-01684-JBS-JS Document 1 Filed 03/06/15 Page 4 of 13 PageID: 4
`
`with the New Jersey Department of Health Food & Drug Safety as a wholesale drug
`
`manufacturer (Registration # 5004419).
`
`13.
`
`Sagent’s 10-K additionally claims that Sagent launched 12 products in 2013, and
`
`had 62 ANDA’s under FDA review at the end of the period. According to Sagent’s 10-K,
`
`Sagent’s FDA approved products include “key” products Cefepime, Levofloxacin, Docetaxel,
`
`Leucovorin Calcium, Zoledronic acid, and Heparin.
`
`14.
`
`Upon information and belief, Sagent intends, upon FDA approval to do so, to
`
`manufacture, distribute and sell the generic equivalents of Baxter’s BREVIBLOC® products in
`
`10 mg/mL 250 mL infusion bags and 20 mg/mL 100 mL infusion bags (see description below of
`
`Sagent’s ANDA relating to these products) that Baxter accuses of infringement in this matter
`
`throughout the United States and in this judicial district.
`
`15.
`
`Upon information and belief, Sagent has previously submitted to and availed itself
`
`of the jurisdiction of this Court for patent infringement suits. See, e.g., Astrazeneca et al. v.
`
`Sagent Pharma Inc., 1:14-cv-05539-RMB-KMW, Novartis v. Actavis et al., 2:13-civ-1028-
`
`SDW-MCA (admitting that it sells generic versions of branded drugs in the United States,
`
`including in New Jersey).
`
`THE DRUG APPROVAL PROCESS
`
`16.
`
`A company seeking to market a new pharmaceutical drug in the United States
`
`must first obtain approval from FDA, typically through the filing of a New Drug Application
`
`(“NDA”). See 21 U.S.C. §355(a). The sponsor of the NDA is required to submit information on
`
`all patents claiming the drug that is the subject of the NDA, or a method of using that drug, to
`
`FDA, and FDA then lists such patent information in its publication, the Approved Drug Products
`
`- 4 -
`
`

`
`Case 1:15-cv-01684-JBS-JS Document 1 Filed 03/06/15 Page 5 of 13 PageID: 5
`
`with Therapeutic Equivalence Evaluations, which is referred to as the “Orange Book.” See 21
`
`U.S.C. §355(b)(1) and (c)(2).
`
`17.
`
`On the other hand, a company seeking to market a generic version of a previously
`
`approved drug is not required to submit a full NDA. Instead, it may file an Abbreviated New
`
`Drug Application (“ANDA”). See 21 U.S.C. §355(j). The generic drug approval process is
`
`considered “abbreviated” because the generic manufacturer may piggyback on the innovator
`
`company’s data and FDA’s prior finding of safety and efficacy by demonstrating, among other
`
`things, that the generic product is bioequivalent to the previously approved drug (the “listed
`
`drug” or “branded drug”).
`
`18.
`
`In conjunction with this “abbreviated” application process, Congress has put in
`
`place a process for resolving patent disputes relating to generic drugs, pursuant to which an
`
`ANDA filer must provide certifications addressing each of the patents listed in the Orange Book
`
`for the branded drug. See 21 U.S.C. § 355(j)(2)(A)(vii); 21 C.F.R. § 314.94(a)(12). An ANDA
`
`filer may certify, for instance, that it believes a patent is invalid or will not be infringed by the
`
`manufacture, use, or sale of the generic drug for which the ANDA is submitted. See 21 U.S.C. §
`
`355(j)(2)(A)(vii)(IV); 21 C.F.R. § 314.94(a)(12)(i)(A)(4). This is known as a “Paragraph IV
`
`Certification.”
`
`19.
`
`The filer of an ANDA with a Paragraph IV Certification must also provide notice
`
`to both the owners of the listed patents and the holder of the NDA for the referenced listed drug.
`
`This “Paragraph IV Notice” must include a detailed statement of the factual and legal bases for
`
`the applicant’s belief that the challenged patent is invalid or not infringed by the proposed
`
`generic product. 21 U.S.C. § 355(j)(2)(B); 21 C.F.R. §314.95.
`
`- 5 -
`
`

`
`Case 1:15-cv-01684-JBS-JS Document 1 Filed 03/06/15 Page 6 of 13 PageID: 6
`
`20.
`
`If the patentee or NDA holder files a patent infringement action within 45 days of
`
`receiving a Paragraph IV Notice from an ANDA filer, final approval of the ANDA is generally
`
`subject to a 30-month stay. See 21 U.S.C. § 355(j)(5)(B)(iii); 21 C.F.R. § 314.107(b)(3). The
`
`30-month stay is important to the innovator companies because it protects them from the severe
`
`financial harm that could otherwise ensue from the FDA granting approval to a potentially
`
`infringing product without first providing an opportunity for the infringement case to be
`
`resolved. Put another way, the innovator company is assured of a 30-month period during which
`
`in may try to enforce its intellectual property rights and resolve any patent dispute before the
`
`generic product enters the market. See 21 U.S.C. § 355(j)(5)(B)(iii).
`
`FACTUAL BACKGROUND
`
`21.
`
`On October 30, 2001, the United States Patent and Trademark Office (“PTO”)
`
`duly and legally issued the ‘094 Patent, entitled “Ready-to-Use Esmolol Solution,” to Baxter
`
`International as assignee. A true and correct copy of the ‘094 Patent is attached as Exhibit A.
`
`22.
`
`On March 4, 2003, the PTO duly and legally issued the ‘540 Patent, entitled
`
`“Esmolol Formulation,” to Baxter International as assignee. A true and correct copy of the ‘540
`
`Patent is attached as Exhibit B.
`
`23.
`
`Baxter International and Baxter HSA are the owners of the ‘094 Patent and the
`
`‘540 Patent.
`
`24.
`
`On February 16, 2001, the FDA approved Baxter Healthcare’s supplemental NDA
`
`No. 19-386/S-018 for BREVIBLOC® Premixed Injection (esmolol HCl in sodium chloride) in
`
`2500mg/250mL IntraVia Containers, under § 505(b) of the Federal Food, Drug and Cosmetic
`
`Act, 21 U.S.C. § 355(b).
`
`- 6 -
`
`

`
`Case 1:15-cv-01684-JBS-JS Document 1 Filed 03/06/15 Page 7 of 13 PageID: 7
`
`25.
`
`On January 27, 2003, the FDA approved Baxter Healthcare’s supplemental NDA
`
`No. 19-386/S-020 for BREVIBLOC® Double Strength Premixed Injection (esmolol
`
`hydrochloride) 20 mg/mL in 100 mL Containers, under § 505(b) of the Federal Food, Drug and
`
`Cosmetic Act, 21 U.S.C. § 355(b) (collectively with the above BREVIBLOC® Premixed
`
`Injection (2500mg/250mL IntraVia Containers), “BREVIBLOC® Premixed Injection Products”).
`
`26.
`
`The BREVIBLOC® Premixed Injection Products are indicated, among other
`
`things, for the rapid control of the heart rate in patients with atrial fibrillation or atrial flutter in
`
`perioperative, postoperative, or other emergent circumstances where short term control of the
`
`heart rate with a short-acting agent is desirable.
`
`27.
`
`Baxter Healthcare is the holder of the NDAs for each of the BREVIBLOC®
`
`Premixed Injection Products. It makes and sells the BREVIBLOC® Premixed Injection
`
`Products to hospitals and other healthcare providers, by exclusive license under the Patents-in-
`
`Suit, throughout the United States.
`
`28.
`
`Plaintiffs jointly own all rights, title and interest in the Patents-in-Suit, including
`
`all rights needed to bring this action in Plaintiffs’ names.
`
`29.
`
`Baxter Healthcare submitted information regarding the ‘094 and ‘540 Patents to
`
`the FDA for listing in the “Orange Book” with respect to the BREVIBLOC® Premixed Injection
`
`Products. The FDA thereafter listed the ‘094 and ‘540 Patents in the Orange Book with respect
`
`to those products, pursuant to 21 C.F.R. § 314.53(e).
`
`30.
`
`Upon information and belief, prior to January 23, 2015, Sagent submitted to the
`
`FDA Abbreviated New Drug Application Number 207107 (the “ANDA”) pursuant to 35 U.S.C.
`
`§ 355(j), seeking approval to engage in the commercial manufacture, use, and sale of proposed
`
`- 7 -
`
`

`
`Case 1:15-cv-01684-JBS-JS Document 1 Filed 03/06/15 Page 8 of 13 PageID: 8
`
`Esmolol Hydrochloride in Sodium Chloride Solution products in dosages of 10 mg/ML 250 mL
`
`infusion bags and 20 mg/mL 100 mL infusion bags (collectively, the “Proposed ANDA
`
`Products”), referencing versions of Baxter’s BREVIBLOC® in plastic container and
`
`BREVIBLOC® double strength in plastic container products.
`
`31.
`
`On or about January 23, 2015, Sagent sent Baxter International a notice stating
`
`that Sagent had submitted ANDA No. 207107 seeking approval to manufacture, use, or sell the
`
`Proposed ANDA products prior to the expiration of the ‘094 Patent and the ‘540 Patent (the
`
`“Paragraph IV Notice”).
`
`32.
`
`33.
`
`Baxter first received Sagent’s Paragraph IV Notice on January 26, 2015.
`
`The Paragraph IV Notice advised Baxter that Sagent’s ANDA included a
`
`Paragraph IV Certification stating that it was Sagent’s opinion that the ‘094 Patent is not valid.
`
`The Notice did not include any assertion that Sagent’s Proposed ANDA Products would not
`
`infringe the claims of the ‘094 Patent. The Notice also stated that it was Sagent’s opinion that
`
`claims 1-6, 8-10, and 12-16 of the ‘540 Patent are invalid, and that Sagent’s manufacture, use,
`
`importation, sale and offer for sale of its Proposed ANDA Products would not infringe claims 7
`
`and 11 of the ‘540 Patent. The Notice did not include any assertion that claims 7-8 and 11 are
`
`invalid, or that claims 1-6 and 9-16 of the ‘540 Patent would not be infringed by Sagent’s
`
`manufacture, use, importation, sale and offer for sale of its Proposed ANDA Products.
`
`COUNT I
`
`INFRINGEMENT OF THE ‘094 PATENT
`
`34.
`
`Baxter incorporates each of the preceding paragraphs 1-33 as if fully set forth
`
`herein.
`
`- 8 -
`
`

`
`Case 1:15-cv-01684-JBS-JS Document 1 Filed 03/06/15 Page 9 of 13 PageID: 9
`
`35.
`
`Sagent’s submission of ANDA No. 207107 to the FDA including the Paragraph
`
`IV Certification submitted therewith, which seeks FDA approval to engage in the commercial
`
`manufacture, use, and sale of its Proposed ANDA Products prior to the expiration of the ‘094
`
`Patent, constitutes infringement of the ‘094 Patent under 35 U.S.C. § 271(e)(2)(A).
`
`36.
`
`Upon FDA approval of ANDA No. 207107, Sagent will directly or indirectly
`
`infringe the ‘094 Patent under 35 U.S.C. § 271(a), (b) and/or (c) by engaging in the commercial
`
`manufacture, use, offer for sale, sale in and/or importation into the United States of the ANDA
`
`Products, and/or by actively inducing and contributing to infringement of others engaging in
`
`such activities, unless this Court orders that the effective date of any FDA approval of Sagent’s
`
`ANDA is no earlier than the expiration date of the ‘094 Patent and any additional periods of
`
`exclusivity.
`
`37.
`
`Baxter has no adequate remedy at law for Sagent’s infringement of the ‘094
`
`Patent, and will be substantially and irreparably harmed by any such infringing activities unless
`
`those activities are enjoined by this Court.
`
`38.
`
`Upon information and belief, Sagent was aware of the existence of the ‘094 Patent
`
`as demonstrated by its reference to that patent in its ANDA, and were aware that the filing of its
`
`Paragraph IV Certification with respect to the ‘094 Patent constitutes infringement of that patent.
`
`This is an exceptional case within the meaning of 35 U.S.C. § 285.
`
`COUNT II
`
`INFRINGEMENT OF THE ‘540 PATENT
`
`39.
`
`Baxter incorporates each of the preceding paragraphs 1-38 as if fully set forth
`
`herein.
`
`- 9 -
`
`

`
`Case 1:15-cv-01684-JBS-JS Document 1 Filed 03/06/15 Page 10 of 13 PageID: 10
`
`40.
`
`Sagent’s submission of ANDA No. 207107 to the FDA including the Paragraph
`
`IV Certification submitted therewith, which seeks FDA approval to engage in the commercial
`
`manufacture, use, and sale of its Proposed ANDA Products prior to the expiration of the ‘540
`
`Patent, constitutes infringement of the ‘540 Patent under 35 U.S.C. § 271(e)(2)(A).
`
`41.
`
`Upon FDA approval of ANDA No. 207107, Sagent will directly or indirectly
`
`infringe the ‘540 Patent under 35 U.S.C. § 271(a), (b) and/or (c) by engaging in the commercial
`
`manufacture, use, offer for sale, sale in and/or importation into the United States of the ANDA
`
`Products, and/or by actively inducing and contributing to infringement of others engaging in
`
`such activities, unless this Court orders that the effective date of any FDA approval of Sagent’s
`
`ANDA is no earlier than the expiration date of the ‘540 Patent and any additional periods of
`
`exclusivity.
`
`42.
`
`Baxter has no adequate remedy at law for Sagent’s infringement of the ‘540
`
`Patent, and will be substantially and irreparably harmed by any such infringing activities unless
`
`those activities are enjoined by this Court.
`
`43.
`
`Upon information and belief, Sagent was aware of the existence of the ‘540 Patent
`
`as demonstrated by its reference to that patent in its ANDA, and were aware that the filing of its
`
`Paragraph IV Certification with respect to the ‘540 Patent constitutes infringement of that patent.
`
`This is an exceptional case within the meaning of 35 U.S.C. § 285.
`
`WHEREFORE, Baxter respectfully requests the following relief:
`
`PRAYER FOR RELIEF
`
`A. A judgment that, pursuant to 35 U.S.C. § 271(e)(2)(A), Sagent has infringed the
`
`‘094 Patent;
`
`- 10 -
`
`

`
`Case 1:15-cv-01684-JBS-JS Document 1 Filed 03/06/15 Page 11 of 13 PageID: 11
`
`B. A judgment that, pursuant to 35 U.S.C. § 271(e)(2)(A), Sagent has infringed the
`
`‘540 Patent;
`
`C. A declaration that Sagent’s commercial manufacture, use, offer for sale, sale in or
`
`importation into the United States of the Proposed ANDA Products would infringe the ‘094
`
`Patent;
`
`D. A declaration that Sagent’s commercial manufacture, use, offer for sale, sale in or
`
`importation into the United States of its Proposed ANDA Products would infringe the ‘540
`
`Patent;
`
`E. An order, pursuant to 35 U.S.C. § 271(e)(4)(A), that the effective date of any
`
`approval of Sagent’s ANDA No. 207107 and/or of the Proposed ANDA Products shall not be
`
`earlier than the expiration date of the ‘094 and ‘540 Patents, including any extensions;
`
`F. A permanent injunction, pursuant to 35 U.S.C. § 271(e)(4)(B), restraining and
`
`enjoining Sagent, its officers, agents, servants and employees, and those persons in active
`
`concert or participation with any of them, from infringement of the ‘094 and ‘540 Patents for the
`
`full terms thereof (including any extensions), including without limitation, enjoining such
`
`persons from commercially making, using, selling, or offering to sell any of the Proposed ANDA
`
`Products within the United States, or importing any such products into the United States, during
`
`the terms of those patents;
`
`G. An order that judgment be entered awarding Baxter monetary relief if Sagent, its
`
`officers, agents, servants and employees, and those persons in active concert or participation with
`
`any of them, commercially make, use, sell, offer for sale in, or import into, the United States, any
`
`of the ANDA Products prior to the expiration of the ‘094 and ‘540 Patents for the full terms
`
`- 11 -
`
`

`
`Case 1:15-cv-01684-JBS-JS Document 1 Filed 03/06/15 Page 12 of 13 PageID: 12
`
`thereof (including any extensions), and that any such monetary relief be awarded with
`
`prejudgment interest;
`
`H. A permanent injunction restraining and enjoining Sagent, its officers, agents,
`
`servants and employees, and those persons in active concert or participations with any of them,
`
`from seeking, obtaining or maintaining final approval of Sagent’s ANDA No. 207107 until
`
`expiration of the ‘094 and ‘540 Patents;
`
`I. A declaration that this is an exceptional case and an award of reasonable
`
`attorneys’ fees pursuant to 35 U.S.C. § 285;
`
`J. Costs and expenses in this action; and
`
`K. Such other and further relief as the Court may deem just and proper.
`
`DECHERT LLP
`
`
`
` /s/ Robert D. Rhoad
`Robert D. Rhoad
`Brian M. Goldberg
`902 Carnegie Center, Suite 500
`Princeton, NJ 08540-6531
`(609) 955-3200
`robert.rhoad@dechert.com
`brian.goldberg@dechert.com
`
`ATTORNEYS FOR PLAINTIFFS BAXTER
`HEALTHCARE CORPORATION, BAXTER
`INTERNATIONAL INC., and BAXTER
`HEALTHCARE S.A.
`
`
`
`
`
`Dated: March 6, 2015
`
`
`- 12 -
`
`
`
`
`
`

`
`Case 1:15-cv-01684-JBS-JS Document 1 Filed 03/06/15 Page 13 of 13 PageID: 13
`
`LOCAL CIVIL RULE 11.2 CERTIFICATION
`
`
`
`Pursuant to Local Civil Rule 11.2, the undersigned attorney for plaintiffs Baxter
`
`Healthcare Corporation and Baxter International Inc. certifies that to the best of his knowledge,
`
`the matter in controversy is not the subject of another action pending in any court or of any
`
`pending arbitration or administrative proceeding. Plaintiffs do note, however, that the patents-in-
`
`suit are the subject of other patent infringement actions pending in this district, encaptioned
`
`Baxter Healthcare Corp. et al., v. HQ Specialty Pharma Corp., C.A. No. 2:13-cv-6228-FSH-
`
`MAH, and Baxter Healthcare Corp. et al., v. Agila Specialties Private Limited, C.A. No. 2:14-
`
`cv-07094-FSH-MAH.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By /s/ Robert D. Rhoad
` ROBERT D. RHOAD
`
`
`
`
`
`
`
`
`
`Dated: March 6, 2015
`
`- 13 -

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket